OG-L002

OG-L002 is an experimental **small-molecule** inhibitor of lysine-specific histone demethylase 1A that has been used as a research tool and preclinical antiviral lead. It potently and selectively inhibits LSD1 activity, with reported selectivity over monoamine oxidase A and monoamine oxidase B, and suppresses herpesvirus gene expression by increasing repressive histone H3K9 methylation at viral immediate-early promoters. In published preclinical studies, OG-L002 has shown activity against herpes simplex virus, including effects on primary infection and reactivation from latency, and has also been studied against other herpesviruses and DNA viruses such as equine herpesvirus 1, human cytomegalovirus, and adenovirus. Based on the provided information, it does not appear to be an approved medicine or an active commercial clinical-development asset by an identified pharmaceutical company.